Cabometyx
Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy
November 30, 2020Sales and Marketing Cabometyx, Japan, Takeda
The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …
Ipsen’s Cabometyx gains European approval in hepatocellular carcinoma
November 16, 2018Medical Communications, Sales and Marketing Cabometyx, carcinoma, ipsen, pharma. European Commission
Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular …
Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer
July 5, 2018Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …
Ipsen receives European first-line approval for Cabometyx
May 17, 2018Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …
Ipsen ends P3 trial on liver cancer early due to strong data
January 18, 2018Research and Development Cabometyx, Exelixis, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …
Ipsen secures NICE approval for multi-targeting kidney cancer therapy
July 11, 2017Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE
Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …
Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial
October 11, 2016Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
Latest content
